Aβ-Generating Enzymes Recent Advances in β- and γ-Secretase Research by Vassar, Robert & Citron, Martin
Neuron, Vol. 27, 419–422, September, 2000, Copyright ª 2000 by Cell Press
MinireviewAb-Generating Enzymes:
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is higher in neurons of the brain. (2) BACE is localized
within acidic intracellular compartments. (3) Overex-
pression of BACE in cells increases b-secretase cleav-
age products; these products start only at known b-secre-
tase cleavage sites. (4) Antisense inhibition of BACE in
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cells decreases b-secretase cleavage. (5) Purified forms
of BACE cleave APP substrates in vitro with correct
b-secretase specificity. (6) BACE has an acidic pH opti-Alzheimer’s Disease (AD) is characterized by two hallmark
mum and is not inhibited by the common aspartic prote-lesions in the brain: the extracellular amyloid plaques, pri-
ase inhibitor pepstatin. Taken together, all the propertiesmarily composed of the 40-42 amino acid Ab peptide, and
of BACE match one-to-one with those of b-secretase.the intracellular neurofibrillary tangles made of abnormally
BACE2phosphorylated tau, a microtubule-associated protein. Al-
Soon after the discovery of BACE, a homologous gene,though the cause of AD is controversial, most evidence
BACE2 (also called Asp1 or Memapsin1), was identifiedsupports a central role for Ab in the pathogenesis of the
by searching genome databases (Saunders et al., 1999;disease (for review, see Selkoe, 1999).
Bennett et al., 2000). BACE and BACE2 share 64% aminoAb is generated by endoproteolytic processing of the
acid similarity and both have a C-terminal transmem-large type I transmembrane protein, amyloid precursor
brane domain. However, BACE and BACE2 are onlyprotein (APP; Figure 1). Enzymes called b- and g-secre-
z40% similar to other aspartic proteases in the pepsintase cleave APP to form the N and C termini, respec-
family, suggesting that BACE and BACE2 define a noveltively, of the Ab peptide. b-secretase is the rate-limiting
family (Figure 2).enzyme in the production of Ab and cleaves APP first
The chromosomal localization of the BACE gene isto form the membrane-bound C99 fragment, which in
11q23.3, a locus not associated with AD, while that ofturn is the substrate of g-secretase (Figure 1). Clearly,
the BACE2 gene is chromosome 21 within the criticalthe b- and g-secretases are excellent therapeutic tar-
Down’s syndrome region (Saunders et al., 1999). There-gets, and major efforts to identify these enzymes have
fore, Down’s patients, who all develop AD by middlebeen pursued for over 12 years. Last fall, the long-sought
age, have three copies each of the APP gene (also onb-secretase was identified as the novel transmembrane
chromosome 21) and the BACE2 gene. This observationaspartic protease BACE (for beta-site APP cleaving en-
suggested that BACE2 may be involved in the AD pathol-zyme), and several recent papers suggest that research-
ogy of Down’s syndrome (Saunders et al., 1999). How-ers may be close to identifying the g-secretase. In this
ever, to date the evidence supporting this hypothesisreview, we discuss these recent advances and their im-
is weak. First, BACE2 is expressed at very low levels inplications for b- and g-secretase research and therapeu-
most neurons of the brain and therefore has a patterntic development.
of expression inconsistent with that expected of b-secre-BACE and b-Secretase Cleavage
tase (Bennett et al., 2000). Importantly, in contrast to BACE,
BACE (also called Asp2 or Memapsin2) was initially dis-
antisense inhibition of BACE2 does not decrease b-secre-
covered in our lab using an expression cloning strategy
tase cleavage in cells (Yan et al., 1999). Finally, recent
to identify genes that influence Ab production (Vassar work has shown that, although BACE2 can cleave APP at
et al., 1999). Subsequently, four other groups identified the b-secretase site, the enzyme cuts more efficiently
BACE either by genomic searches for novel aspartic within the Ab domain and therefore may limit the produc-
proteases or by protein purification methods (Hussain tion of pathogenic Ab species (Farzan et al., 2000).
et al., 1999; Sinha et al., 1999; Yan et al., 1999; Lin et Posttranslational Processing of BACE
al., 2000). Thus, five groups employing three different BACE undergoes a series of posttranslational modifica-
approaches led to the identification of the same enzyme, tions, including glycosylation, disulfide bond formation,
making a very strong case that BACE is b-secretase. and propeptide processing. On SDS-PAGE, BACE mi-
The BACE polypeptide sequence contains two con- grates at z70 kDa, much higher than the predicted z50
served D(T/S)G(T/S) motifs that form the active site of kDa, indicating that BACE is heavily glycosylated. There
aspartic proteases of the pepsin family. BACE is an are four predicted N-linked sites in BACE, all of which are
unusual aspartic protease because it has a C-terminal glycosylated, but there appears to be no O-glycosylation
transmembrane domain and is therefore membrane (Haniu et al., 2000). An z60 kDa immature form is initially
bound. The two active site motifs are located in the made in the ER and undergoes rapid maturation to an
luminal domain, so both the active site of BACE and the z70 kDa form as a result of complex glycosylation in
b-secretase cleavage site of APP are in correct topologi- the Golgi apparatus (Haniu et al., 2000; Capell et al.,
cal orientation for endoproteolysis (Figure 1). 2000). BACE has six luminal cysteine residues that form
Extensive analysis of BACE by the five groups has three intramolecular disulfide bonds connecting C278
demonstrated that BACE exhibits all the characteristics to C443, C216 to C420, and C330 to C380 (Haniu et al.,
of b-secretase. (1) BACE is expressed in all tissues but 2000). This disulfide bond structure is not typical of
aspartic proteases, and it may play a role in determining
BACE enzymatic properties. Finally, BACE is synthe-* To whom correspondence should be addressed (e-mail: rvassar@
amgen.com). sized with a propeptide domain that is cleaved at residue
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Figure 3. Two Models for the Role of Presenilin in g-Secretase
Cleavage
(A) Presenilin is g-secretase. The N- and C-terminal fragments of
presenilin (green) associate with a stabilizing factor (pink), and the
presenilin transmembrane aspartates (D) are juxtaposed to form the
active site of g-secretase.
(B) Presenilin is a critical cofactor in the g-secretase complex. The
presenilin fragments, together with the stabilizing factor, bind to an
as yet unidentified g-secretase (blue) that comprises the active siteFigure 1. Schematic of b- and g-Secretase Cleavages
of a multiprotein enzyme complex.
The b- and g-secretase cleavage sites in APP and C99, respectively,
are indicated by arrows, and the Ab domain is represented by the
red rectangle. N and C signify amino and carboxyl termini, respec-
model is correct, compounds designed to bind thesetively, of APP, BACE and presenilin (PS). The cell membrane is
residues with high affinity should be potent BACE inhibi-shown in orange. The Ds in BACE and PS are proposed active site
aspartates, and the three loops in BACE indicate disulfide bonds. tors. However, unequivocal identification of the impor-
tant active site residues must await determination of the
X-ray structure of BACE cocrystallized with substrate.
E46 to form the mature enzyme. The sequence immedi- Properties of g-Secretase
ately preceding the cleavage site is RLPR, a potential Following b-secretase cleavage, a second cut at the C
recognition motif of proprotein convertases such as terminus of the Ab peptide by the g-secretase is neces-
furin, and mutation of R45 to alanine blocks propeptide sary to release Ab from C99 (Figure 1). g-secretase can
processing (Capell et al., 2000). Furin, or a furin-like cleave at multiple positions and thus generates Ab pep-
protease, is likely to mediate BACE propeptide cleavage tides of different lengths. The predominant species,
because: (1) the furin-specific inhibitor a1-antitrypsin Ab40, is formed by cleavage after the 40th amino acid
PDX blocks BACE propeptide cleavage; (2) BACE propep- of Ab. Cleavage after the 42nd amino acid creates Ab42,
tide is not processed in the furin-deficient Lovo cell line; which accounts for only about 10% of total secreted
and (3) in vitro, furin cleaves the propeptide domain of Ab. Despite lower production, Ab42 appears to be the
purified BACE exactly at the E46 site (Bennett et al., 2000). major pathogenic species because it is increased in the
It remains to be determined whether processing of the various forms of familial early onset AD and is the major
propeptide domain may regulate the activity of BACE. constituent of the amyloid plaques. g-secretase cleav-
Regardless, furin does not appear to be a viable AD thera- ages occur within the predicted transmembrane domain
peutic target given its ubiquitous pattern of expression of APP, requiring g-secretase to either cleave within the
and large number of important substrates in vivo. lipid bilayer or change the conformation of C99 such
Important questions remain concerning the design of that the cleavage sites are pulled out of the membrane
BACE inhibitors for therapeutic development. Critical (for review, see Selkoe, 1999). Site-directed mutagene-
for drug design will be the structural elucidation of the sis studies suggest that the enzyme has a rather broad
BACE active site bound with substrate. Toward this goal, sequence specificity, quite in contrast to b-secretase.
Sauder et al. (2000) have modeled BACE in complex This has led to the hypothesis that g-secretase may not
with various APP substrates and propose that R296 and need a specific recognition sequence but may cleave
several hydrophobic residues in the active site may play various type I transmembrane proteins that lack a bulky
critical roles in the enzyme–substrate interaction. If the luminal or extracellular domain. g-secretase has not yet
been purified, and much of the currently available infor-
mation is derived from cell-based assays. It is unclear
from these studies whether the same g-secretase gener-
ates both Ab40 and Ab42, or whether different enzymes
are responsible for the two cleavages. Inhibitor data
supporting both scenarios have been published. It ap-
pears that the majority of g-secretase cleavage leading
to secreted Ab takes place in late transport compart-
ments and in the endosomal pathway.Figure 2. Evolutionary Tree Showing the Relationships between
Presenilin Is Required for g-Secretase CleavageBACE, BACE2, and Other Aspartic Proteases
and Notch SignalingBACE and BACE2 form a novel family of transmembrane aspartic
proteases that are most closely related to the pepsin family (i.e., The presenilins PS1 and PS2 were first described by
pepsinogen A, pepsinogen C, cathepsin D, cathepsin E, and renin). geneticists investigating mutant genes that cause domi-
The homodimeric retroviral aspartic proteases, including those from nant early onset familial AD (for review, see Sisodia et
Moloney murine leukemia virus (MMLV asp), human immunodefi- al., 1999). A large number of mutations in PS1 and a
ciency virus (HIV asp), and Rous sarcoma virus (RSV asp), are evolu-
few in PS2 cause familial AD characterized by globallytionarily more ancient than the BACE and pepsin families (from
increased Ab42 production even in presymptomatic mu-Bennett et al., 2000; reproduced with permission from J. Biol.
Chem.). tation carriers. Moreover, expression of mutant prese-
Minireview
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nilins in transfected cells or transgenic mice leads to explained by the provocative hypothesis that PS1 and
PS2 themselves are g-secretase with PS1 contributingoverproduction of Ab42 (but not Ab40 or other APP
metabolites), suggesting that the mutant forms specifi- the majority of cleavage activity (Wolfe et al., 1999). This
hypothesis is clearly supported by the loss of g-secretasecally affect g-secretase cleavage. More recently, knock-
out studies have demonstrated that endogenous wild- activity in PS knockout cells. However, there is no obvious
protease active site in either PS1 or PS2.type PS1 and PS2 are required for g-secretase cleavage.
Cells derived from PS1 knockout mice show 80% reduc- Inhibitor data suggesting that g-secretase may be an
aspartic protease led to the mutational analysis of twotion in both 40 and 42 cleavage, and in cells from PS1/
PS2 double knockouts g-secretase cleavage is com- conserved aspartates in transmembrane domains 6 and
7 of presenilins that were hypothesized to provide thepletely abolished (Zhang et al., 2000).
Presenilins are not only involved in g-secretase cleav- active sites. When the aspartates were mutated, g-secre-
tase and Notch cleavages were markedly decreased, sup-age: they also control the Notch signaling pathway that
is important for cell fate decisions during embryogene- porting the hypothesis that PS1 and PS2 are novel aspartic
proteases that cleave both APP and Notch (Wolfe et al.,sis, hematopoiesis, and neuronal stem cell differentia-
tion (for review, see Haass and De Strooper, 1999). In 1999). However, a subsequent detailed analysis demon-
strated that, while both PS1 aspartic acid residues arethis multistep pathway, presenilins are specifically re-
quired for the proteolytic cleavage within the transmem- critically required for Notch cleavage, only one of the two
is required for g-secretase cleavage (Capell et al., 2000).brane domain of the Notch protein, which releases the
Notch intracellular domain for signaling in the nucleus. This result is inconsistent with a model in which both
aspartates contribute to the active site, as one wouldPS1 and PS2 are widely expressed homologous inte-
gral membrane proteins for which an eight-transmem- expect from the known aspartic proteases.
The strongest evidence that PS may be g-secretasebrane structure has been proposed (Figure 1). They do
not show obvious homologies to known receptors, ion comes from two recent studies that used labeled bona
fide g-secretase inhibitors to identify proteins close tochannels, or proteases and within neurons are primarily
found in the ER and the early Golgi. In tissues and cells, the active site of g-secretase (Esler et al., 2000; Li et al.,
2000b). Both studies identified presenilin using differentpresenilins do not occur as uncleaved holoproteins but
primarily in a proteolytically cleaved stable form con- assay systems and different inhibitors. Esler et al. (2000)
used g-secretase pathway inhibitors with micromolar IC50sisting of an N- and a C-terminal fragment in a complex
with other proteins. While a detailed discussion of pre- in intact cells and microsome preparations, whereas Li
et al. (2000b) used nanomolar inhibitors in a cell- andsenilin metabolism is beyond the scope of this review,
experiments from several laboratories have led to the organelle-free in vitro system consisting of a recombi-
nant C99 substrate and their solubilized g-secretasefollowing consensus. (1) Overexpression of presenilin
leads to the synthesis of holoprotein, which is short complex (Li et al., 2000a) as source of enzyme. An aspar-
tic protease inhibitor with an active site–directed transi-lived. Separately overexpressed presenilin N- and C-ter-
minal fragments are also short lived. It appears that tion state analog was derivatized to contain a photoreac-
tive group at two positions within the molecule, and thepresenilin proteins need to interact with an unknown
factor to become stabilized. (2) This stabilization occurs resulting compound demonstrated nanomolar IC50 in
the in vitro assay. It could therefore be assumed thatbefore endoproteolytic cleavage, but the cleavage is not
absolutely required for stabilization (uncleavable forms upon photoactivation these derivatives would specifi-
cally label protein(s) very close to or containing the ac-of presenilin can be stabilized). (3) Cells contain low
levels of presenilin complexes. When exogenous pre- tive site of g-secretase. Using this approach, the authors
identified the PS1 and PS2 N- and C-terminal fragmentssenilin is overexpressed in cells, most of the overex-
pressed protein is rapidly degraded, but some of it ap- as specifically labeled. It was further shown that only
PS1 derivatives known from cell-based experiments toparently titrates out the stabilizing factor and replaces
endogenous presenilin in the complex (for review, see be biologically active were labeled with the inhibitor.
Upon overexpression of PS1, only the fragments wereHaass and De Strooper, 1999; Sisodia et al., 1999).
g-Secretase Activity Is Associated labeled, but not the rapidly degraded wild-type holopro-
tein. In contrast, an uncleavable but biologically activewith the Presenilin Complex
A recent publication has reported partial purification PS1 mutant holoprotein was also labeled.
Together, these studies provide strong evidence thatfrom membrane preparations of a large complex that
exhibits g-secretase activity on C99-like substrates. Re- PS1 contains the active site of g-secretase. However,
one has to assume that the inhibitors label the proteincovery of the catalytically active complex from mem-
branes critically depends upon the choice of detergent containing the active site of g-secretase rather than a
contiguous protein. The study of Li et al. (2000b) specifi-for solubilization. The large complex catalyzes both 40
and 42 cleavage at a ratio similar to that found in intact cally suggests that the active site of g-secretase is
shared between the presenilin N- and C-terminal frag-cells. Activity of the complex is inhibited by g-secretase
pathway inhibitors previously identified in cell-based ments, because, depending on the localization of the af-
finity label within the inhibitor, either the N- or theassays and by the aspartic protease inhibitor pepstatin.
Interestingly, an antibody against the PS1 N-terminal C-terminal fragment is labeled (Figure 3A). However, the
firm conclusion that presenilin is g-secretase or containsfragment pulls out soluble g-secretase activity (and the
PS1 C-terminal fragment), indicating that PS1 expression at least the active site of a multiprotein complex with
g-secretase activity does require the in vitro reconstitu-is not only required for g-secretase activity in intact cells,
but that PS1 protein is physically associated with the tion of g-secretase from purified components. At this
point, an alternative model in which presenilin is a criticalg-secretase enzyme (Li et al., 2000a). These data can be
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press.question is not only of academic interest. If presenilin
Esler, W.P., Kimberly, W.T., Ostaszewski, B.L., Diehl, T.S., Moore,is g-secretase, then it is also the Notch cleaving enzyme.
C.L., Tsai, J.-Y., Rahmati, T., Xia, W., Selkoe, D.J., and Wolfe, M.S.
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g-secretase inhibitors that do not inhibit Notch cleavage.
Farzan, M., Schnitzler, C.E., Vasilieva, N., Leung, D., and Choe, H.
This clearly raises some concerns for using g-secretase (2000). Proc. Natl. Acad. Sci. USA 97, 9712–9717.
inhibitors in chronic treatment for AD, although it is cur- Haass, C., and De Strooper, B. (1999). Science 286, 916–919.
rently unknown what level of Notch cleavage reduction
Haniu, M., Denis, P., Young, Y., Mendiaz, E.A., Fuller, J., Hui, J.O.,
can be tolerated in the actual treatment situation with Bennett, B.D., Kahn, S., Ross, S., Burgess, T., et al. (2000). J. Biol.
adult human patients. Consistent with this scenario, Chem. 275, 21099–21106.
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already been shown to also inhibit Notch cleavage (for man, C., Gloger, I.S., Murphy, K.E., Southan, C.D., Ryan, D.M., et
al. (1999). Mol. Cell. Neurosci. 14, 419–427.review, see Haass and De Strooper, 1999). On the other
Li, Y.-M., Lai, M.-T., Xu, M., Huang, Q., DiMuzio-Mower, J., Sardana,hand, if presenilin were a critical cofactor in two different
M.K., Shi, X.-P., Yin, K.-C., Shafer, J.A., and Gardell, S.J. (2000a).complexes, one containing g-secretase and the other
Proc. Natl. Acad. Sci. USA 97, 6138–6143.containing a distinct Notch cleaving enzyme, one could
Li, Y.-M., Xu, M., Lai, M.-T., Huang, Q., Castro, J.L., DiMuzio-Mower,possibly distinguish between the two activities pharma-
J., Harrison, T., Lellis, C., Nadin, A., Neduvelil, J.G., et al. (2000b).cologically. The fact that some presenilin mutations, in-
Nature 405, 689–694.
cluding mutation of the first aspartate in PS1, have been
Lin, X., Koelsch, G., Wu, S., Downs, D., Dashti, A., and Tang, J.reported to affect Notch but not g-secretase cleavage
(2000). Proc. Natl. Acad. Sci. USA 97, 1456–1460.
(Capell et al., 2000) is consistent with the latter scenario.
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Research on the b- and g-secretases has made aston- 300, 241–248.
ishing progress over the past several months. The role
Saunders, A.J., Kim, T.-W., Tanzi, R.E., Fan, W., Bennett, B.D., Babu-
of BACE in mediating b-secretase cleavage is now firmly Khan, S., Luo, Y., Louis, J.-C., McCaleb, M., Citron, M., et al. (1999).
established, and the definitive molecular identification of Science 286, 1255a.
the g-secretase appears imminent. However, important Selkoe, D.J. (1999). Nature 399, 23–31.
questions remain to be addressed. As for b-secretase, Sinha, S., Anderson, J.P., Barbour, R., Basi, G.S., Caccavello, R.,
are there other enzymes in addition to BACE that have Davis, D., Doan, M., Dovey, H.F., Frigon, N., Hong, J., et al. (1999).
Nature 402, 537–540.b-secretase activity, and what are the biological roles of
BACE and BACE2 (besides cleaving APP)? The answers Sisodia, S.S., Kim, S.H., and Thinakaran, G. (1999). Am. J. Hum.
Genet. 65, 7–12.may determine how well BACE drugs are able to block
Vassar, R., Bennett, B.D., Babu-Khan, S., Kahn, S., Mendiaz, E.A.,Ab production, whether or not potential side effects will
Denis, P., Teplow, D.B., Ross, S., Amarante, P., Loeloff, R., et al.be associated with BACE inhibition, and if drug cross-
(1999). Science 286, 735–741.reactivity between BACE and BACE2 is desirable or un-
Wolfe, M.S., Xia, W., Ostaszewski, B.L., Diehl, T.S., Kimberly, W.T.,wanted. BACE and BACE2 gene knockout experiments
and Selkoe, D.J. (1999). Nature 398, 513–517.will provide the first steps toward addressing these is-
Yan, R., Bienkowski, M.J., Shuck, M.E., Miao, H., Tory, M.C., Pauley,sues. Given the successful efforts to develop inhibitors
A.M., Brashler, J.R., Stratman, N.C., Mathews, W.R., Buhl, A.E., etof HIV protease and renin, both aspartic proteases, it is
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possible that BACE inhibitors will be developed and
Zhang, Z., Nadeau, P., Song, W., Donoviel, D., Yuan, M., Bernstein,
advanced into the clinic for AD. Important for this goal A., and Yankner, B.A. (2000). Nat. Cell Biol. 2, 463–465.
will be solving the crystal structure of BACE, thus
allowing the application of rational drug design meth- Note Added in Proof
ods. Regarding g-secretase, the issue of whether pre-
Shortly after this minireview went to press, a novel transmembranesenilins are g-secretase or essential cofactors for an
glycoprotein called nicastrin was identified and shown to be tightlyunknown g-secretase remains debatable. As mentioned
associated with presenilin in the g-secretase multiprotein complexabove, unequivocal resolution of this issue will require
(Yu et al., 2000). Nicastrin also binds C99, the immediate precursor
the in vitro reconstitution of g-secretase from purified of Ab, and missense mutations in a conserved hydrophilic domain
components. Because of the significant therapeutic in- of nicastrin cause an increase in Ab40 and Ab42 secretion, while
terest in g-secretase inhibitors, which have already en- deletion of this domain results in reduced Ab generation. The effects
of the nicastrin mutations are analogous to those of presenilin muta-tered clinical trials, it seems likely that the problems of
tions that modulate the production of Ab peptides. The polypeptideg-secretase biochemistry will be solved in the near fu-
sequence of nicastrin does not resemble that of a protease or anyture. Finally, the efficacy of b- and g-secretase inhibitors
other protein with known function. The authors suggest that nica-in the treatment of AD patients will provide the ultimate
strin may function to either bind substrates of g-secretase or regu-
test of the amyloid cascade hypothesis, thus bringing to late g-secretase activity. While it remains to be seen whether muta-
an end a debate that has raged for nearly two decades. tions in the nicastrin gene associate with certain AD pedigrees, the
work of Yu et al. (2000) clearly demonstrates that nicastrin is an
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